(TGTX) TG Therapeutics - Ratings and Ratios
Briumvi, Ublituximab, TG-1701, TG-1801
TGTX EPS (Earnings per Share)
TGTX Revenue
Description: TGTX TG Therapeutics
TG Therapeutics Inc (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company focused on developing novel treatments for B-cell mediated diseases. The company has a diverse pipeline of investigational medicines, including BRIUMVI, an anti-CD20 monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (RMS). Other key assets include Ublituximab IV, a glycoengineered anti-CD20 mAb, and TG-1701, an orally available Brutons tyrosine kinase (BTK) inhibitor.
The companys commercialization strategy is supported by multiple license agreements with partners such as LFB Biotechnologies S.A.S and Novimmune SA. With a market capitalization of approximately $5.97 billion, TG Therapeutics has demonstrated significant growth potential. Key performance indicators (KPIs) to watch include revenue growth from BRIUMVI sales, pipeline development milestones, and the expansion of its commercial presence in the global biopharmaceutical market.
From a financial perspective, the companys price-to-earnings (P/E) ratio of 150.40 and forward P/E of 42.92 indicate a high-growth expectation. Return on Equity (RoE) stands at 18.88%, suggesting efficient use of shareholder capital. To further evaluate the stocks potential, its essential to monitor its ability to maintain support levels, particularly around $34.7 and $33.6, and break through resistance levels at $37.3 and $39.2.
To assess the companys future prospects, investors should keep a close eye on upcoming clinical trial results, regulatory approvals, and commercial milestones. Additionally, monitoring the competitive landscape and developments in the multiple sclerosis treatment market will be crucial in understanding TG Therapeutics potential for long-term success.
TGTX Stock Overview
| Market Cap in USD | 5,103m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1995-12-14 |
TGTX Stock Ratings
| Growth Rating | 60.5% |
| Fundamental | 60.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 7.78% |
| Analyst Rating | 4.43 of 5 |
TGTX Dividends
Currently no dividends paidTGTX Growth Ratios
| Growth Correlation 3m | -63.9% |
| Growth Correlation 12m | 46.6% |
| Growth Correlation 5y | -1.9% |
| CAGR 5y | 72.94% |
| CAGR/Max DD 3y | 0.90 |
| CAGR/Mean DD 3y | 2.64 |
| Sharpe Ratio 12m | 0.44 |
| Alpha | 0.30 |
| Beta | 0.511 |
| Volatility | 72.75% |
| Current Volume | 2126.9k |
| Average Volume 20d | 1894k |
| Stop Loss | 30.8 (-3.9%) |
| Signal | 0.53 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (60.5m TTM) > 0 and > 6% of Revenue (6% = 27.2m TTM) |
| FCFTA -0.06 (>2.0%) and ΔFCFTA -22.68pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 108.4% (prev 80.90%; Δ 27.47pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.08 (>3.0%) and CFO -59.1m <= Net Income 60.5m (YES >=105%, WARN >=100%) |
| Net Debt (115.9m) to EBITDA (59.5m) ratio: 1.95 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (162.6m) change vs 12m ago 1.97% (target <= -2.0% for YES) |
| Gross Margin 86.96% (prev 92.71%; Δ -5.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 82.27% (prev 86.42%; Δ -4.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.89 (EBITDA TTM 59.5m / Interest Expense TTM 31.4m) >= 6 (WARN >= 3) |
Altman Z'' -5.31
| (A) 0.70 = (Total Current Assets 664.0m - Total Current Liabilities 171.9m) / Total Assets 702.6m |
| (B) -2.13 = Retained Earnings (Balance) -1.50b / Total Assets 702.6m |
| warn (B) unusual magnitude: -2.13 — check mapping/units |
| (C) 0.11 = EBIT TTM 59.3m / Avg Total Assets 551.9m |
| (D) -3.51 = Book Value of Equity -1.50b / Total Liabilities 426.2m |
| Total Rating: -5.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.42
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -0.75% = -0.38 |
| 3. FCF Margin -8.93% = -3.35 |
| 4. Debt/Equity 1.51 = 1.46 |
| 5. Debt/Ebitda 7.01 = -2.50 |
| 6. ROIC - WACC (= 5.66)% = 7.07 |
| 7. RoE 26.05% = 2.17 |
| 8. Rev. Trend 79.79% = 5.98 |
| 9. EPS Trend 49.15% = 2.46 |
What is the price of TGTX shares?
Over the past week, the price has changed by +0.68%, over one month by +15.54%, over three months by -8.46% and over the past year by +27.75%.
Is TG Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TGTX is around 29.43 USD . This means that TGTX is currently overvalued and has a potential downside of -8.15%.
Is TGTX a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the TGTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 40.5 | 26.4% |
| Analysts Target Price | 40.5 | 26.4% |
| ValueRay Target Price | 32.5 | 1.4% |
Last update: 2025-09-16 04:41
TGTX Fundamental Data Overview
CCE Cash And Equivalents = 129.1m USD (Cash only, last quarter)
P/E Trailing = 84.6316
P/E Forward = 42.9185
P/S = 11.2377
P/B = 18.4591
Beta = 1.881
Revenue TTM = 454.1m USD
EBIT TTM = 59.3m USD
EBITDA TTM = 59.5m USD
Long Term Debt = 245.0m USD (from longTermDebt, last quarter)
Short Term Debt = 171.9m USD (from totalCurrentLiabilities, last quarter)
Debt = 416.9m USD (Calculated: Short Term 171.9m + Long Term 245.0m)
Net Debt = 115.9m USD (from netDebt column, last quarter)
Enterprise Value = 5.39b USD (5.10b + Debt 416.9m - CCE 129.1m)
Interest Coverage Ratio = 1.89 (Ebit TTM 59.3m / Interest Expense TTM 31.4m)
FCF Yield = -0.75% (FCF TTM -40.6m / Enterprise Value 5.39b)
FCF Margin = -8.93% (FCF TTM -40.6m / Revenue TTM 454.1m)
Net Margin = 13.31% (Net Income TTM 60.5m / Revenue TTM 454.1m)
Gross Margin = 86.96% ((Revenue TTM 454.1m - Cost of Revenue TTM 59.2m) / Revenue TTM)
Tobins Q-Ratio = -3.60 (set to none) (Enterprise Value 5.39b / Book Value Of Equity -1.50b)
Interest Expense / Debt = 1.61% (Interest Expense 6.72m / Debt 416.9m)
Taxrate = 8.64% (2.21m / 25.6m)
NOPAT = 54.2m (EBIT 59.3m * (1 - 8.64%))
Current Ratio = 3.86 (Total Current Assets 664.0m / Total Current Liabilities 171.9m)
Debt / Equity = 1.51 (Debt 416.9m / last Quarter total Stockholder Equity 276.4m)
Debt / EBITDA = 7.01 (Net Debt 115.9m / EBITDA 59.5m)
Debt / FCF = -10.28 (Debt 416.9m / FCF TTM -40.6m)
Total Stockholder Equity = 232.1m (last 4 quarters mean)
RoA = 8.60% (Net Income 60.5m, Total Assets 702.6m )
RoE = 26.05% (Net Income TTM 60.5m / Total Stockholder Equity 232.1m)
RoCE = 12.42% (Ebit 59.3m / (Equity 232.1m + L.T.Debt 245.0m))
RoIC = 13.03% (NOPAT 54.2m / Invested Capital 415.5m)
WACC = 7.38% (E(5.10b)/V(5.52b) * Re(7.86%)) + (D(416.9m)/V(5.52b) * Rd(1.61%) * (1-Tc(0.09)))
Shares Correlation 3-Years: 87.88 | Cagr: 1.68%
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -40.6m)
EPS Correlation: 49.15 | EPS CAGR: 64.72% | SUE: -0.09 | # QB: 0
Revenue Correlation: 79.79 | Revenue CAGR: 1329 % | SUE: N/A | # QB: None
Additional Sources for TGTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle